Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 119

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 119
---
 may not receive any cash proceeds from the exercise of such Warrants. An active trading market for our Common Stock may not be available on a consistent basis to provide stockholders with adequate liquidity. The price of our Common Stock may be extremely volatile, and stockholders could lose all or part of their investment. The trading price of our Common Stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this “ Risk Factors” section and elsewhere in this prospectus, these factors include:

| ● | the commencement, enrollment or results of any planned and future preclinical studies and clinical trials of our product candidates or changes in the development status of our product candidates; |

| ● | any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings; |

| ● | adverse results from or delays in preclinical studies and clinical trials of our product candidates, including as a result of clinical holds, safety events, enrollment difficulties, or study protocol amendments; |

| ● | our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; |

| ● | adverse regulatory decisions, including failure to receive regulatory approval of our drug to market for our product candidates; |

| ● | adverse developments concerning our manufacturers; |

62

| ● | our inability to obtain adequate product supply for any approved drug or inability to do so at acceptable prices; |

| ● | our inability to establish collaborations, if needed; |

| ● | our failure to commercialize our product candidates; |

| ● | additions or departures of key scientific or management personnel; |

| ● | unanticipated serious safety concerns related to the use of our product candidates; |

| ● | introduction of new drugs by our competitors; |

| ● | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; |

| ● | any significant change in our management; |

| ● | our ability to effectively manage our growth; |

| ● | the size and growth of our initial target markets; |

| ● | actual or anticipated variations in quarterly operating results; |

| ● | our cash position; |

| ● | our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; |

| ● | the public’s response to press releases or other public